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INTRODUCTION 
  
 Carcinoma of the oral cavity is the second most common cancer in India and 
fourth most common in Madras Metropolitan Tumor Registry
 (1)
. Cervical nodes form 
the first echelon of metastases in cancers of the oral cavity. The frequency of cervical 
nodal metastases varies depending on the subsite, tumour size, depth of invasion, 
tumour grade, etc. The treatment of cervical nodal metastases from oral cancers 
depends on the number, size, and level of nodal spread; it can be surgery, radiation, 
chemotherapy or their combinations. Clinically node negative (N0) patients form a 
specific subset among oral cancers for whom the treatment of neck is not well 
standardised. Treatment options include observation, elective neck dissection or 
elective neck irradiation and depends on various factors like risk category, patient 
preference, treatment availability, treatment for the primary, physician preference etc. 
The chance of occult metastases in clinically N0 disease can be up to 30 percent
 (2)
. 
Elective treatment of neck is recommended in high risk groups defined as those 
patients with risk of lymph node metastasis risk more than 20 percent
 (3).  
If the neck is 
not addressed while adequately treating the primary, there is a high chance of nodal 
recurrence in those patients who harbor metastases 
(3).
  
          Clinical examination with imaging modalities like ultrasound, computed 
tomography (CT) scan, magnetic resonance imaging (MRI) and positron emission 
tomography (PET) scan are not sensitive enough to exclude occult neck nodes in 
clinically N0 patients
(3)
.  
          Sentinel lymph node is the first echelon node and often first site of metastases. 
Histological status of sentinel node may predict micro-metastases in the reminder of 
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lymphatic basin. The technique of Sentinel lymph-node biopsy (SLNB) has been 
successfully applied in carcinoma of breast and melanoma. Extrapolating these 
concepts, it would be ideal to do a complete neck dissection only in patients with 
positive sentinel nodes. This could spare the morbidity of the neck dissection in up to 
70 percent of patients 
(4)
. With this background we tried to evaluate sentinel lymph 
node using methylene blue dye in clinically node negative oral cavity cancers at 
Government Royapettah Hospital.  
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AIM OF THE STUDY 
 
Primary Aim:  
The primary aim of this study is to evaluate the feasibility and efficacy of 
sentinel lymph node using methylene blue dye in clinically node negative early stage 
oral cavity cancers in avoiding morbidity of neck dissection. 
Secondary Aims:  
(1) To identify most common site of sentinel lymph node for oral cancers. 
(2) Usefulness of USG imaging in assessing neck metastasis not apparent 
clinically. 
(3) Correlation of sentinel node with non-sentinel node metastases   
(4) Assessing possibility of level IIB, IV and V sparing neck dissections in 
oral cancers N0 neck 
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REVIEW OF LITERATURE 
 
Introduction:     
Carcinoma of oral cavity is more prevalent in the areas of tobacco abuse. It is 
more common in men, with a male to female ratio of 2.3:1
(5)
. The risk of nodal 
metastases increases with increasing “T’ status and grade of the tumor and specific 
subsites like tongue, FOM and alveolus. The presence of metastatic neck node is the 
single most important adverse prognostic factor. The 5-year survival rate decreases to 
below 50 percent when cervical nodal metastases are present 
(6,7,8)
. The lymphatic 
metastases from head and neck cancers follow a well-defined pattern. In the absence 
of metastasis to levels I, II and III, the involvement of levels, IV and V are rare 
(exception being tongue)
 (7).
  
Lymphatic Anatomy: 
The prime function of the lymphatic system is the return of proteins, 
interstitial fluid and immune cells back to the bloodstream. These elements initially 
enter the lymphatic capillary vessels which are lined by non-gapped continuous 
endothelial cells. Lymphatic fluid flows in smaller collecting vessels (2 layered) and 
then into larger collecting vessels (3 layered), which finally drain into lymph nodes 
(9) 
(fig-1)
. Afferent lymphatic vessels enter the convex surface of lymph node and drain 
into the marginal sinus. Medullary sinuses receive lymph from the marginal sinus and 
penetrate the medulla of the lymph node. Efferent lymphatic vessels formed by 
coalescence of lymphatic channels in medulla exit via the hilum. Lymph flows 
through the node in a unidirectional manner. Afferent lymphatics may at times bypass 
certain lymph nodes in their path
 (10).
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Variations in anatomy of lymphatics have been described by Ludwig
 (11)
 
(Figure 2). 
Figure 1 Lymph Node Anatomy 
 
Figure 2 Types of Lymphatic Drainage 
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Lymphatic Flow Pattern in Head and Neck: 
 The head and neck region has a dense and complicated network of lymphatic 
channels. It accounts for a third of the total number of lymph nodes in the human 
body (approximately 200 to 350 lymph nodes). Lymph nodes of the head and neck 
are divided into superficial and deep groups. The superficial lymphatics and nodes lie 
between the skin and the superficial fascia. Deep cervical nodes are present deep to 
the sternocleidomastoid muscle, along the internal jugular vein from the base of skull 
to the brachiocephalic junction. Efferent lymphatics drain into the venous system at 
that junction.  
Lymphatic drainage from specific regions of the Upper-Aero-Digestive-Tract 
(UADT) 
(12,13) 
follow a predictable pattern according to the preferential pathways of 
natural lymph flow (Werner and Davis
(14)
). Lymphatics of the neck have been 
organized into four functional drainage pathways 1). The main lymphatic pathway, 
2).The posterior pathway, 3). The anterior lymphatic pathway and 4). The superficial-
lateral pathway. The works of Lindberg, Byers et al.
 (15)
 (1988), and Shah et al.
 (16)
  
(1990)
 
were among the many studies that were vital in understanding the lymphatic 
basins at risk of metastasis from Squamous Cell Carcinoma (SCC) arising from 
specific sub-sites of the UADT. 
However, it is important to emphasize that, inspite of these widely accepted 
generalized patterns of lymphatic drainage; there is wide variability in the lymphatic 
flow of the head and neck region
 (17). 
This variability is confirmed by studies 
performed at the Moffit Cancer Center, Miami, which has shown as much as a 63 
percent discordance between a patient’s predicted lymphatic drainage based on classic 
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pathways as opposed to the patient’s actual lymphatic anatomy imaged by a 
lymphoscintigram
(17)
 
In 2004, American Head and Neck Society agreed upon a classification 
system of six lymph node levels proposed by Robbins et al., 2000
(18)
 which has been 
widely accepted. Knowledge of the primary tumor site and understanding of the 
pathways of lymphatic tumor spread helps to predict the region of the neck at highest 
risk for metastatic disease.  
Lymphatic drainage of oral cavity 
(19)
: 
Lymph from the central part of the lower lip drains to the submental lymph 
nodes. Lateral parts of the lower lip, upper lip and the mucous membrane of the cheek 
drain to the submandibular lymph nodes. Both surfaces of the lower gingivae and the 
outer surface of the upper gingivae drain into submandibular lymph nodes. The inner 
surface of the upper gingiva is drained by the vessels of the hard palate to the upper 
deep cervical lymph nodes. The floor of the mouth drains anteriorly via lymphatics 
that pierce the mylohyoid muscle to reach the submental nodes or posteriorly to the 
submandibular nodes. The submandibular and submental nodes drain into the deep 
cervical nodes from where the lymph finally empty in the jugular trunk.  
Types of Neck Dissections 
(20)
: 
Treatment options of the neck in clinically node positive patients (N+) mostly 
depend on the treatment of the primary lesion. Radiation or chemo radiation to the 
neck is given if primary lesion is treated by radiation, and neck dissection should be 
performed if primary lesion is managed by surgery. An academic classification of 
neck dissections is shown in Table 1 and the types are described below. 
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Table 1 Classification of Neck Dissections 
Neck dissections classification 
Comprehensive Neck Dissections Selective Neck Dissections 
Radical neck dissection. Supraomohyoid neck dissection (level I-III). 
Modified radical neck dissection 
Posterolateral neck dissection 
(level II, III, IV, V) 
Extended radical neck dissection Lateral neck dissection (Level II-IV) 
 Anterior neck dissection (VI) 
 
1. Radical neck Dissection: 
In radical neck dissection, all cervical lymph node groups from levels I to V were 
removed as enbloc with the Spinal Accessary Nerve, Internal jugular vein, and 
Sternocliedomastoid muscle on one side.   
2. Modified Radical Necks Dissection: 
In modified radical neck dissection, all lymph nodes routinely removed by the 
radical neck dissection are removed with preservation of one or more the important 
non lymphatic structures i.e. Spinal Accessary Nerve, Internal jugular vein, and 
Sternocliedomastoid muscle.   
3. Extended Neck Dissection: 
 Extended neck dissection refers to the removal of one of more additional 
lymph node groups’ like retropharyngeal, superior mediastinal, buccinators and para 
tracheal lymph nodes and/or non lymphatic structures like the hypoglossal nerve, 
vagus nerve, paraspinal muscles, skin, external carotiod, etc.   
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4. Selective Neck Dissection: 
 A selective neck dissection refers to dissection of lymph node groups which 
are at high risk of involvement based on the lymphatic anatomy of the primary. For 
oral cavity cancers, the lymph nodes at greatest risk are located in levels I, II, and III. 
The lymph nodes at risk for oropharyngeal, hypopharyngeal, and laryngeal cancers 
are located in levels II, III, and IV, for thyroid cancer the lymph nodes are level VI, II, 
III, IV, V. (Table 1) 
If a neck dissection is carried out when there is no evidence of neck disease it 
is termed an "elective" neck dissection (END). Some authors use the word 
"prophylactic" instead of "elective" to denote the same procedure. If the neck 
dissection is undertaken for metastatic disease in the neck it is called a "therapeutic" 
neck dissection 
Clinically Node Negative Patients (N0): 
Though the treatment of neck in N+ patients has been well studied and 
established, the treatment of neck in clinically N0 patients remains controversial. 
Clinically N0 patients harbor a risk of having occult metastases in the neck in upto 30 
percent. Patients with high risk for occult metastasis,
(6,7,8)
 are identified by 
characteristics of the primary lesion thickness of >4 mm and size >2 cm, anatomic 
location, lympho vascular invasion, perineural infiltration, poorly differentiated 
histology and immunosuppression.(Table 2) Cervical node metastasis is the single 
most important adverse prognostic factor with drop in overall 5 years survival from 
82 to 53 percent. Hence it seems logical to intervene early rather than watchful 
waiting, as delayed resection in clinically evident macroscopic disease have poor 
prognosis 
(21)
. 
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Table 2 Risk of Occult Neck Node Metastases in Oral Cancers 
Group 
Risk of occult 
metastases 
Stage Primary site 
High risk >30% 
T1-4 
Nasopharynx, pyriform sinus,  
base of tongue 
T2-4 
Soft palate, pharyngeal wall, supraglottic 
larynx, tonsil 
T3-4 
Anterior 2/3
rd
 tongue , FOM, RMT, 
Gingiva, Hard palate, Buccal mucosa 
Intermediate 
risk 
20-30% 
T1 
Anterior 2/3
rd
 tongue, soft palate, 
pharyngeal wall, supraglottic larynx, 
tonsils 
T2 
Anterior 2/3
rd
 tongue , FOM, RMT, 
Gingiva, Hard palate, Buccal mucosa 
Low risk <20% T1 
FOM, RMT, Gingiva, Hard palate, 
 Buccal mucosa 
 
Modalities for treatment of N0 neck: 
(22,23) 
The management options for the clinically N0 neck include (1) selective neck 
dissection with the rationale of regional staging and elective treatment, (2) irradiation 
of the neck as elective treatment, and (3) observation- clinical follow-up with option 
of therapeutic neck dissection or irradiation if patients develop detectable neck nodal 
disease.  
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Elective irradiation of neck has several limitations. It is more morbid and 
provides no staging information to estimate prognosis or guide further management. 
Few treatment alternatives exist in those who develop second primary tumors which 
occurs in about 2-4%/year
 (23)
. 
Selective neck dissection (I-III) offers comparable local control rates with less 
morbidity when compared with radiotherapy and other types of neck dissection in 
SCC of oral cavity. Sometimes close observation is sufficient if the primary lesion is 
of T1 stage.  
More precise staging before treatment is mandatory to prevent the 
consequences of inappropriately selected management strategies for the clinically N0 
neck in oral cancer. The concept of sentinel node biopsy may fulfill the requirement. 
The surgeon should have experience with a minimum of 10 cases before undertaking 
SLNB as a staging tool.   
Methods to identify occult lymph node metastases: 
1. Noninvasive methods:  
The radiological assessment of neck in clinically node negative patients has 
improved with recent advances in imaging techniques. Contrast-enhanced CT and 
MRI are the common imaging modalities used to evaluate the neck in oral cancers. 
Radiological criteria for nodal involvement include size (Levels I, II ≥ 1.5 cm, Levels 
III – VI ≥ 1.2 cm), number of nodes (3 lymph nodes > 8 mm), central necrosis, 
irregular enhancement and poorly defined or irregular capsules 
(24,25)
. PET scan has 
poor sensitivity in detecting micro-metastases in the neck
 (26)
. The combined use of 
ultrasound with fine needle aspiration may also identify patients requiring neck 
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dissection 
(27)
. However the available methods reach only 80–85% sensitivity and 
require experienced and skilled operators 
(27)
. (Table 3) 
Table 3: Comparison of imaging modalities in Occult Metastases in N0 Neck 
Modality Sensitivity Specificity 
Ultrasound 
(24)
 50-58% 75-82% 
CT
(24) 
 40-68% 78-92% 
MRI
(24)
 55-93% 82-95% 
PET
(26)
 87-90% 80-93% 
CT-PET
(26)
 96% 98.5% 
 
2. Invasive methods: 
1. Pre-operative dynamic / static scintigraphy with or without SPECT 
2. Blue dye technique 
3. Hand held Gamma probe aided detection of SLNB. 
4. Combination of two or more techniques.  
 
Sentinel lymph node biopsy - Historical perspective  
Regional lymph node dissection (RLND) is based on existing knowledge of 
tumour spread through lymphatics. The varied frequency of lymph node metastases in 
various cancers depending on the primary tumour characteristics challenges the role 
for routine RLND or its modifications in all patients with nodal disease. Sentinel node 
biopsy may offer a solution to this dilemma.  
In 1955, Seaman and Powers 
(28)
 laid the groundwork for lymphoscintigraphy 
and lymphatic mapping. Gould et al 
(29)
 independently observed that the routine 
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excision of a ‘‘sentinel node’’ found at the origin of the common facial vein at the 
time of parotidectomy offered diagnostic significance. The “'Cabanas approach (30)' 
introduced in 1977 is less reliable because of the relatively crude localization 
techniques based on anatomy only. In 1992 Morton 
(31)
 et al used cutaneous 
lymphoscintigraphy as a method to identify the nodal basins at risk of metastases in 
melanomas located in ambiguous sites. Alex and Krag 
(32)
 in 1996 reported the first 
successful sentinel node biopsy in a case of supraglottic cancer. While 
lymphoscintigraphy improved and assay techniques increased in sensitivity, 
preferential drainage to one or two nodes in the lymph nodal basin was consistently 
demonstrated which made application of SNB technique more common 
(33)
. 
 
Sentinel Lymph Node Biopsy – Concept and Principles 
Tumour cell progression within the lymphatic system follows an orderly 
pattern. Primary or the draining lymph nodes possess the structural and functional 
capability to filter and entrap tumour cells efficiently. Thus removing uninvolved 
lymph nodes may be harmful to the patient from an immunological point of view.  
Sentinel node biopsy is a minimally invasive, diagnostic procedure which can 
accurately predict the presence/ absence of nodal metastases. It offers a reliable 
method to avoid lymphadenectomy. The success of SLNB depends on two factors: 
the accuracy of the localisation technique to identify the sentinel lymph node, and its 
intraoperative feasibility. The finding of gross cancer involvement contraindicates 
sentinel node biopsy and mandates formal lymphadenectomy.  
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Figure 3: Concept of Sentinel Lymph node 
 
 
The three essential principles of SLNB are: 
(34) 
1. A predictable and orderly pattern of tumour spread from the primary to 
regional lymph nodes. 
2. The lymph node effectively filters the afferent lymph whereby the tumour 
cells get entrapped in it. 
3. There is a sequential progression of tumour cells from the first echelon to 
second echelon nodes.  
4. Unidirectional spread due to lymphatic valves. 
There is sufficient evidence available to support these three basic principles in 
head and neck cancers 
(35,36)
. 
 
Sentinel Lymph Node Biopsy (SLNB) is applicable for staging the following 
(37)
: 
1. Ipsilateral clinically N0 neck drained by a unilateral primary tumor 
2. Bilateral clinically N0 neck drained by a midline tumor or crossing the 
midline 
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3. Contralateral clinically N0 neck drained by a midline tumor or tumor crossing 
the midline in the presence of a clinically positive ipsilateral neck. 
De Boer et al
(38)
 showed a statistically significant difference in disease free 
survival (DFS) in head and neck cancers between SLN-negative and patients with 
micro metastases or ITCs. Pitman KT
 (39) et al
 showed that patients with micro 
metastases had an intermediate prognosis between patients who are node-negative 
and those with macro metastases. Sentinel lymph nodes identified in the context of 
elective neck dissection is called as SNB-assisted elective neck dissection 
(39)
. 
Additional pathologic methods of serial sectioning and immunohistochemical 
analysis of sentinel nodes have upstaged up to 8% of neck dissection specimens in 
patients with head and neck 
(40)
. 
To date, SLNB can be considered as the most accurate way to stage the cN0 
neck
(41) 
.The SLN with the highest radioactive count may be the most likely to harbor 
tumor cells. Studies in patients with breast cancer reported a considerable false-
negative rate of SLNB (9% to 29%) if only the hottest SLN was removed.
42
 Atula et 
al
43 
demonstrated that, in Oropharyngeal SCC it was sufficient to dissect the 3 hottest 
lymph nodes to detect occult metastases in all patients. 
Sentinel Lymph Node Biopsy - Physiology of Lymphoscintigraphy: 
(44-46) 
 
Lymphoscintigraphy (LS) is the study used for localization of lymph nodes 
draining a specific anatomic area. It uses after intraepithelial, subepithelial, or intra-
parenchymal injection of identifiable particles of appropriate size into the interstitium. 
The particles enter lymphatic capillaries and flow to the lymph nodes where they are 
phagocytosed by macrophages. Successful SLNB requires patent lymphatic channels 
as well as normally functioning lymph nodes. It also requires that the percentage of 
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particles trapped in the more proximal nodes is greater than the percentage of 
particles that flow to distal lymph nodes. 99mTc sulfur colloids are common for 
lymphoscintigraphy. The advantages are:  
1. They emit only gamma rays and have low radiation exposure 
2. Half-life is only 6 hr and peak energy emission peak of 140 keV, within the 
detection range of most handheld gamma probes. 
Particle size is the primary factor that determines the rate of uptake and filtration 
within the sentinel node. The optimal particle size of radioisotopes is between 5 and 
10nm. Particles smaller than 5nm are absorbed by the vascular system.  
SLNB usually uses a triple diagnostic approach. Twenty four hours prior to 
operation, radiocolloid is injected around the primary tumor site and static 
lymphoscintigraphy is used to identify the location of the sentinel node(s). 
Intraoperative identification is done using both blue dye and hand-held gamma probe. 
Sentinel Lymph Node Biopsy - Lymphoscintigraphy Technique: 
Static and dynamic imaging, are two modes of obtaining lymphoscintigraphy. 
Optimum pre-operative information is obtained by dynamic imaging, due to the short 
distance from primary site to sentinel node, complexity of the anatomy and variable 
pattern of lymphatic drainage. 
Early imaging (<30 min post injection) 
i) SLNB- Hotspots with evident uptake    
ii) 2nd echelon - Caudal hotspot with clearly visible connecting lymphatic 
vessel from a cranial hotspot, not increasing in time 
iii) Caudal hotspot with low uptake not increasing in time 
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Late static imaging (2–4 hr post injection) 
i) SLNB-New hotspots visualized ipsilaterally or contralaterally.  
ii) New hotspots visualized between a hotspot already identified during early 
imaging and the injection site. 
iii) Caudal hotspots with a previously low uptake, but now much more 
intense. 
iv)  Newly visualized hotspot also considered to be a sentinel node. 
Tumors in the oral cavity other than mobile tongue and FOM tumors seem to 
have slower lymphatic drainage; an early lymphatic imaging was able to identify 
hotspots in only 29% of patients with these tumors 
(44)
.  Heuveling et al
 (44)  
believes 
that late lymphoscintigraphic imaging should be considered for these tumors to 
minimize the risk of false-negative results. The same is true for paramedian and 
midline tumors, for which bilateral drainage was observed in the majority (83%) of 
tumors, half of them visible only during late imaging 
(44)
. 
SLNB may also prove useful for those patients with clinically established 
ipsilateral neck disease, with an N0 contra-lateral neck clinically but are at risk of 
contra-lateral neck involvement 
(44)
. In such patients lymphoscintigraphy may 
establish the presence of bilateral drainage, and sentinel node biopsy can spare them 
the morbidity of elective treatment to opposite neck. SPECT/CT offers better 
anatomical localisation than planar lymphoscintigraphy but may not improve the 
outcome of the sentinel node procedure itself 
(46)
. Acquisition time of SPECT is much 
longer compared with that of planar lymphoscintigraphy, and SPECT imaging is 
often performed as the final imaging procedure – that is, at a later time point after 
injection of 99mTc-Nanocoll – second echelon lymph nodes containing radiocolloid 
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may become visible on SPECT images 
(46)
. Furthermore, additional hotspots detected 
next to the hotspot that was identified on planar LS should also be detected 
intraoperative by the gamma probe. Haerle et al
 (46) 
believe that SPECT-CT imaging is 
a helpful additional tool for detailed localization of a hotspot, but not for 
identification of true SNs. 
 
Sentinel Lymph Node Biopsy – Using the Gamma camera 
(47)
: 
 A hand held Gamma camera probe is used for detection of radioactivity. It 
should be passed slowly over the neck at a steady rate, aimed away from the primary 
resection bed to assess the auditory input for radioactivity. As the probe measures 
radioactivity with time, rapid or unsteady movement leads to higher readings and 
louder auditory input, and should be avoided. Any lymph node with atleast 10% of 
the radioactivity of the most radioactive node in the same anatomic area is considered 
an additional sentinel lymph node and is harvested separately. Relatively hot nodes in 
a different anatomic region that does not reach 10% of the radioactivity of the hottest 
node but has atleast 2 times radioactivity of the background readings must also be 
harvested as a sentinel node,  as it may represent a separate drainage pattern from a 
different portion of the tumor.  
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Table 3A : Comparison between techniques for localization: 
Study  No. of 
patients 
SLN 
identified 
True 
positive 
False 
negative 
Sensitivity 
(%) 
Shoaib et al 
35
 13-blue 
13-radio 
5 
12 
0 
7 
3 
0 
41 
100 
Civantos 
65 
(two) 
except blue 
43 43 18 2 90 
Stoeckli 
67 
(triple) 
79 78 29 2 94 
Ross 
89 
(triple) 134 125 42 3 93 
 
Sentinel Lymph Node Biopsy – Drawbacks 
(48,49)
:  
The disadvantages of SLNB are 
1. Skip metastasis alter management predictions. 
2. Learning curve  
3. Radionuclide retention in tissues. 
4. Failure to identify sentinel nodes 
5. Free soft tissue disease not taken into account 
Frozen sections are unreliable to detect micro-metastasis and hence occult 
metastasis
 (50)
. Sentinel lymph node biopsy is an acceptable procedure for microscopic 
disease; however clinical disease must be ruled out with clinical examination after 
induction of anesthesia. 
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For oral cancer, it appears that the sentinel node is an excellent tool for 
assessment of microscopic disease, but subclinical gross disease must be sought by 
radiologic studies and intraoperative palpation 
(51)
. 
Sentinel Lymph Node Biopsy - Failure to Identify Sentinel Nodes: 
(52-53)
 
For T3 and T4 primary tumors difficulty in injecting the dye around tumor 
may alter the pickup rate requiring large volumes for these tumor, other reason for 
failure of SLNB technique include excessive uptake of radioactivity, potential for 
false-negatives caused by incomplete injection, and technical  futility of removing a 
large number of nodes in piecemeal fashion. Bulky or deeply infiltrative primary 
tumors that invade adjacent anatomic subsites clearly pose technical difficulties for 
peritumoral injection. 
Clinical node positivity predicts failure of the technique to identify sentinel 
node, hence anterior tongue and FOM are subsites with reduced success rate due to 
high risk of node positivity (20-30%). 
FOM tumors lesions are the most difficult sub site for SLNB 
(53)
. The lymph 
from the floor of mouth drains through nodes along lingual nerve (lingual nodes) to 
cervical nodes. Uptake in the lingual nodes and level I nodes overlap with the 
injection site uptake and SLNB may be missed. It is referred as the ‘‘shine through’’ 
phenomenon 
(53)
.  
The mandible interferes with the gamma camera probe angulation. The 
technical difficulty may be overcome with several solutions like software masking, 
lead shields, removing the primary tumor prior to SLNB identification, and elective 
dissection of level I nodes can be useful but sentinel nodes for FOM remains 
problematic. Higher successful harvest rate is seen in patients with a positive 
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preoperative lymphoscintigraphy (94%) compared with patients with a negative 
preoperative lymphoscintigraphy (79%)  
Delayed sentinel lymph node biopsy (D-SLNB) is defined as any SLNB 
procedure that is carried out after a previous wide local excision of the primary. A 
delay or more than 90 days, or cicatrix after Wide Local Excision alters lymph 
draining channels rendering the procedure unreliable and SLNB non-representative of 
the original lymphangiosome. 
Sentinel Lymph Node Biopsy - Enhanced pathological review 
(54-60)
: 
 A successful procedure relies on efficient screening by the pathologist. Extent 
to which SLNB upstages the neck by traditional pathologic methods seems to be 
similar to that with elective neck dissection. The use of additional pathologic methods 
results in perhaps an even greater level of detection of disease. The negative 
predictive value of frozen section ranges from 83 to 99% 
(55) 
depending on the slicing 
technique used and is higher for multi-slice technique 
(55)
. Unlike frozen section, 
imprint cytology can also be used where concern about loss of tissue during 
processing does not exist 
(55)
. 
Serial sectioning has to be done with more attention than usual. Tumor cells 
enter the node through the opposite side of hilum. SLNs less than 0.5 cm are 
processed entirely, nodes up to 1 cm are halved and sentinel lymph node more than 
1cm are downsized to 0.5 cm and step sections are made if first section is negative. 
While cutting the step ribbons, one portion is retained for IHC and other for routine 
HPE staining 
(57)
. Without step sections and immunohistochemistry, up to 15 to 20% 
of metastases may be missed 
(76)
. Therefore, the theoretical sensitivity for detection of 
metastases by single HE frozen section analysis is (under optimal conditions) not 
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higher than 80 to 85% 
(58)
. These small deposits of occult disease are likely to be 
overlooked by the routine histological assessment of the large number of nodes in a 
neck dissection specimen.  
Sentinel Lymph Node Biopsy - Rapid Molecular Detection as an Intraoperative 
Adjunct 
(60)
: 
Frozen section results vary with pathologist and technical staff. Since 
sensitivity is not very high, molecular detection came in to practice for the last 2 
years. It is quick, has high negative predictive value and facilitates one time surgery
 
(60)
. Use of qRT-PCR (Reverse Transcriptase associated Polymerase Chain Reaction) 
permits quick and reliable assessment and can be useful tool in decision making. Per 
operative molecular staging with PCR amplification of marker genes could spare 60-
70% of pN0 patients from unnecessary surgery 
(60)
. 
Sentinel Lymph Node Biopsy - Classification and Staging 
(61)
:  
UICC definitions of metastatic deposits divided into macrometastasis (>2 mm), micro 
metastasis (0.2-2 mm) and even small tumour cells or small clusters <0.2 mm 
(isolated tumour cells, ITC).     
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Sentinel Lymph Node Biopsy - Outcomes: 
Three prospective studies and good quality of SLNB are in progress namely 
SENT 
(62)
, DAHANCA 22 
(63)
, Brazilian Head & Neck Group 
(64)
. Recently the 
prospective multi-institutional clinical trial by ACOSOG Head and Neck Committee 
has shown encouraging results 
(65)
. The Efficacy of Sentinel Node Biopsy in Head and 
Neck Cancers in various studies are shown in Table 4. 
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Table 4 Efficacy of Sentinel Node Biopsy in Head and Neck Cancers 
Author No. of 
Patients (n) 
SLNB 
Identification 
rate 
NPV Occult 
Metastases (n) 
Ross et al 
(2005) 
(66)
 
134 125/134 96% 39 (33%) 
Stoeckli et 
al.(2008)
 (67)
 
79 79/79 100% 26 (32%) 
Alkusheri et al 
(2010) 
(68)
 
134 125/134 94.6% 42 (34%) 
Melakane et al 
(2012) 
(69)
 
166 154/166  95.2% 42 (25%) 
Antanio et al 
(2012) 
(70)
 
209 183/209 94.9% 54 (29.5%) 
 
Sentinel Lymph Node Biopsy – the consensus in literature 
(71)
: 
1) Negative predictive value is between 90% and 100%. 
2) Step serial sectioning and IHC are essential parts of the procedure. 
3) IHC and step serial sectioning yields better results and significantly improve the 
negative predictive value of this technique. 
4) Compared to Lymphadenectomy SLNB significantly upstages nodal stages. 
5) Unexpected patterns of lymphatic drainage can indeed occur, including 
unanticipated contralateral drainage to nodes that might be missed in standard 
lymphadenectomy 
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6) Frozen section, imprint cytology, and molecular biology based technique permits 
quick and reliable assessment of nodes facilitating the neck dissection at the same 
sitting if appropriate.  
Following are significant concerns. Staged surgery is required in a small 
group when positive nodes are found after formal processing at later date.  
The best treatment of neck with single micro metastasis or even isolated tumor 
cells is elusive 
(72)
. It has been proposed that removal of the sentinel node alone may 
be sufficient in these patients but without strong evidence 
(73)
.  
 
Selective Neck Dissections and post-operative shoulder dysfunction syndrome: 
 Subclinical spinal accessory nerve impairment can be observed even after 
selective neck dissections (levels I-III) due to routine clearance of sublevel II B 
(74)
. 
The most common morbidity associated with selective neck dissection (SND-I-III) is 
spinal accessory nerve dysfunction and related shoulder disability 
(75,76) 
. Nerve 
morbidity is mainly due to stretching while clearing level IIB nodes. If these nodes 
are not dissected the above mentioned morbidity can be prevented. 
 Even after careful dissection of the posterior triangle, unavoidable trauma to 
the accessory nerve (SAN) does occur. Potential reason for the nerve dysfunction 
includes traction injury, use of diathermy and vascular injury. Postoperative 
hemorrhage, infection and scarring may affect nerve function. Apart from injury to 
SAN, connections with the cervical plexus are damaged invariably during dissection 
of Level V. All these factors lead to shoulder syndrome. This syndrome is 
characterized by shoulder pain, weak abduction, and winging scapula. These 
symptoms may lead to significant restrictions in patient’s professional and every day 
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activity 
(77)
. Pinsolle et al (1997) 
(77)
 found in a series  of 41 patients following 
supraomohyoid neck dissection, 32% to have minor, 5% moderate, and 2.5% severe 
shoulder problems. Paul van et al (2003) 
(78) 
in a study of 58 patients showed 14 
(28%) shoulder dysfunction. 
Is Level II B removal necessary? 
 Involvement of IIb nodes is rare in clinically N0 oral cavity cancers 
(79-82)
. 
This has led to the idea of preserving them to avoid trauma to Spinal Accessory 
Nerve. This is anticipated to have a better functional out come and reduced morbidity 
(80, 81)
. The review of literature (Table 5) suggests that metastatic involvement of level 
IIb is rare based on from both elective and therapeutic neck dissection. 
Table 5 Involvement of Level IIB Nodes 
Author No. of Neck 
Dissections 
Level IIb 
no. and (%) 
Exclusive  Level IIb 
involvement 
Lim et al [2004]  
Elsheikh et al [2005] 
(79)
 
Lim et al [2006] 
(80)
 
Villaret et al [2007] 
(81)
 
Manola et al 2011 
(82)
 
74 
48 
125 
43 
34 
4(6.7) 
1(2) 
8(6.4) 
26(5.6) 
0 
0 
1 
0 
2 
0 
 
 It shows Level IIb involvement ranges between 2- 6.5% in cN0 neck. But in 
presence of clinically palpable nodes and level II involvement metastasis increase 
upto 22—36% (106). Hence, routine clearance of IIb is not necessary in N0 neck.  
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Is Level IV and V clearance necessary? : 
 In clinically N0 neck of oral cavity cancers, level IV and V nodes are not 
first echelon nodes. Skip metastasis to level IV & V are rare. Shah JP et al (1990) 
(83)
 
found that in oral cavity cancers occurrence of level IV metastases was 3% in N0 
neck and 17% in node positive neck and the prevalence of neck metastases in level V 
is 0.5% in N0 and 3% in node positive. Davidson et al (1993) 
(84)
 in a review of 1123 
patients who underwent a neck dissection for squamous cell carcinoma of the head 
and neck and reported a 3% incidence of histologically positive nodes at level V, with 
1% for N0 and 5% for node positive patients. 
 Dissection of level IV is associated with two important complications injury 
to thoracic duct (left), and injury to phrenic nerve. Dissection of Level V can cause 
injury to spinal accessory nerve, transverse scapular vessels, cervical plexus and 
brachial nerve plexus. Dissection of level V area is also associated with shoulder 
dysfunction syndrome. Hence sparing these groups of lymph nodes in elective neck 
dissection of clinically negative neck can decrease the morbidity without 
compromising oncologic cure 
(85)
. 
Rationale for the present study: 
 There is continuing debate over management of clinically negative neck. 
Since occult neck node metastases is about 30% there is high probability that neck 
can be under staged if only clinical examination is used to stage the neck. Imaging 
modalities like ultrasound CT scan and MRI have contributed in detecting metastatic 
nodes in clinically negative neck, but no imaging modality is capable of diagnosing 
micro-metastases in less than 5mm node. 
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 Sentinel lymph node biopsy is a promising tool slowly gaining popularity in 
Head neck cancers. It is reasonably accurate in predicting nodal metastases. Apart 
from conventional histopathological techniques serial sectioning, routine use of 
immuno-histochemistry and more recently use of molecular markers have improved 
the detection of nodal metastases. Combination of these two tools may give even 
superior and accurate staging information. 
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MATERIAL AND METHODS 
 
Study design:  
 This prospective pilot study was carried out in Department of Surgical 
oncology with collaboration of Department of pathology and Radiology, Government 
Royepettah Hospital, Chennai. Patients of oral cancer with clinically negative neck 
are included in the study, after obtaining informed consent. Thirty two patients with 
oral cancers with stages T1-T3, N0 were included in the study. 
 
Inclusion criteria:  
        1. Patients with oral cancer clinically negative neck nodes. 
       2. Patients above 18 years age with ability to give consent. 
 
Exclusion Criteria: 
         1. Patient with T4 tumour 
         2. Patients primarily treated by radiotherapy. 
         3. Patients who had previous surgery in neck.  
         3. Patients with palpable nodes. 
         4. Patients who are not medically fit to undergo surgery. 
         5. Histology other than Squamous cell carcinomas. 
         6. Patients not willing to participate in the study. 
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Clinical Evaluation:  
          Comprehensive history was taken and through clinical examination carried out.  
      Details about age, sex, religion, any family history of head and neck cancer were 
recorded. History of tobacco chewing, pan, quid, smoking and alcohol were enquired. 
Symptoms like ulcer, pain bleeding, hyper salivation, etc. elaborated in detail. Oral 
cavity examined for any pre-malignant conditions like leukoplakia, sub-mucus 
fibrosis. Side, T stage of the tumor and type of tumor noted. Neck is examined for 
palpable lymph nodes. Only patients who were clinically negative for lymph nodes 
were taken in for the study. 
Ultrasound Examination: 
       Ultrasound examination is done with real time scanner with probe head of 7.5 
MHz frequency transducer. The neck is examined longitudinal and transversely in 
continuous sweep technique   covering from the thoracic inlet to the sub mentum. If 
any found on ultrasound the level, size, echogenicity and other characteristics is 
noted.  
Sentinel lymph node biopsy (SLNB): 
         Patients in the study were injected with 2 ml of methylene blue dye 
peritumorally at 3, 6, 9 and 12’ clock position (0.5 ml in each quadrant) in the 
operating room after anesthesia. Stop clock is started to set the maximum limit as 20 
minutes. Lymph nodes were harvested between 10 – 20 minutes and if dissection 
exceeds beyond 20 min, the patient was excluded from the study. 
 Neck incision is marked as per the convenience of surgeon (crile’s, hemi-
apron). Tumescent is injected along the marked incision and sub platysmal flaps are 
raised superiorly and inferiorly.  
Sentinel Lymph Node Biopsy in Oral Cancers 
 
31 
 
 Then visual inspection of the draining area is done for the blue colored node, 
before removal of any lymphatic tissue. Any blue node found is dissected out 
separately and sent for Frozen & histopathological examination. If Lymph node has 
not taken the stain then blue stained lymphatics were sought and traced till the 
draining lymph node and the same node is treated as sentinel node. Presence or 
absence of blue nodes, number of nodes and the level of nodes were noted. 
 Selective neck dissection is completed from Level Ia, Ib, IIa, IIb, III, IV 
separately.   
 Frozen section and serial sections of the sentinel lymph node is prepared with 
hematoxylin and eosin stain and examined under microscope for macro or micro 
metastasis or isolated tumor cells. Immunohistochemistry using pancytokeratin 
marker was done at a later date to detect occult disease. 
Neck dissection: 
 All patients are subjected to selective neck dissection. Lymph nodes are 
retrieved from all levels and sublevels separately. Lymph nodes are labeled as Level 
Ia, Level Ib, Level IIa, Level IIb, Level III, Level IV. Type of neck dissection, 
number of lymph nodes in each dissection is recorded. The number of lymph nodes 
from each level and sub level noted separately. Histopathological examination is done 
with routine hematoxylin and eosin staining. Involvement of Level IIb, Level IV was 
specifically recorded. 
Postoperative Histopathology:   
1) Primary tumor: Post-operative specimen of primary tumor is examined under 
hematoxylin and eosin stain after preparing paraffin sections. Tumor Grade, 
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margin, tumor thickness, vascular invasion, peri-neural invasion, Lymphatic 
invasion and muscle invasion are noted.   
2) Lymph nodes of neck:       
       Number of nodes harvested at each level and sub-level is noted. Lymph nodes are 
examined after fixing and staining for metastasis, extra capsular spread.  
Follow up: 
 All patients are followed up and advised adjuvant treatment as appropriate. 
They are examined regularly for any evidence of loco-regional and distant metastases 
monthly for the first 2 years, when there is highest chance of recurrence. For the next 
year every second monthly review is done.       
Outcome Measures: 
 The primary outcome of the study was to analyze the feasibility of sentinel 
lymph node assisted selective neck dissections in clinically N0 patients using blue 
dye. The secondary outcome measures were- i) analyses the incidence and level of 
involvement of lymph nodes in carcinoma oral cavity. ii) Correlation with tumor 
stage and grade. iii) Comparison of accuracy of neck staging with SLNB to neck 
dissection. iv) Identification of factors predicting the node positivity in oral cavity 
cancers. v) Evaluation of the necessity of level IIB, IV clearance in neck dissections. 
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Table 6 Boundaries of Neck Dissection (ref- as defined by MSKCC group) 
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STATISTICAL ANALYSIS 
 
Statistical analysis was done with SPSS for Windows, 16.0 version (® SPSS 
Inc, USA). Quantitative data are described as mean and standard deviations. 
Categorical data are shown as Proportions. Data are also presented graphically with 
bar diagrams and pie charts. Data were explored for any outliers, typing errors and 
missing values. Comparison of groups was carried out for various categorical 
variables using Chi-square test of association.  A p-value (two-tailed) < 0.05 was 
taken as significant. 
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RESULTS AND OBSERVATIONS 
 
In our study of 32 patients of whom 24 (75%) were male and 8(25%) with 
mean age 43 (26-70) years, right (n=16) and left (n=16) sided tumor were equal.  
Clinical Tumour status T1, T2 and T3 in this study were 16 (50%), 14 (43.7%), 2 
(6.3%) respectively. 19 (59.7%) patients were smokers, 10 (31.2%) were alcoholic, 
9(28%) patients used tobacco quid and others forms tobacco usage occurred in7 
(21%) (Table 7) 
Table 7: General Patient Characteristics 
General Patient characteristics: No. of patients Percentage 
Age distribution 
26-70 (mean 43 years) 
Less than 50 years 14 43.8% 
50 years & above 18 56.3% 
Sex distribution Male 24 75% 
Female 8 25% 
Addictions Smoking( cigar, beedi) 19 59.4% 
Smokeless tobacco 16 50 % 
Alcohol 10 31.3% 
Laterality Left 16 50% 
Right 16 50% 
Clinical tumour staging T1 16 50.0% 
T2 14 43.8% 
T3 2 6.3% 
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Tongue was the most common site involved in a 18 (56%), followed by 
buccal mucosa 7 (22%) then hard palate 2(6%), retro-molar trigone 2(6%), hard 
palate 2 (6%) floor of mouth 1(3%) (Figure-4) Morphologically ulcero-proliferative 
type is the most common occurring in 16 (50%) patients and other types include 
ulcerative, infiltrative and verrucous type in 8 (25%), 6 (18.8%), 2 (6.3%) 
respectively (figure-5). 
Symptoms like ulcer occurred in 18 (56.3%) patients, or ulcer with pain 
12(37.5%), hyper salivation, difficulty in swallowing and referred otalgia are less 
common mode of presentation in our early tumors (one patient each) (figure-6). 
Patients presented within and after 4 months were 21 (65.6%) and 11 (34.4%) 
respectively. Earliest reported was 15 days and longest was 11 months. Correlation of 
duration with T stage and grade was not significant (table 8 and 9) 
Table 8 Duration of Symptoms vs. T stage 
Duration T1(n=16) T2(n=14) T3(n=2) Total(n=32) 
2 months or less 2 (50%) 2 (50%) 0 4 
3-4 months 10 (58.8%) 6 (35.3%) 1 (5.9%) 17 
More than 4 months 4 (36.4%) 6 (54.5%) 1 (9.1%) 11 
Total 16 14 2 32 
Chi-square value: 1.934; P= 0.748 
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Figure 4: Tumour Subsite 
 
Figure 5: Morphology of Tumour 
 
Figure 6: Frequency of symptoms 
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Nineteen patients (59.3%) had well differentiated, 12(37.5%) moderately 
differentiated and 1(3.2%) poorly differentiated tumours. Correlation of grade with T 
stage and duration of symptoms was not significant (table9 and 10). 
Table 9 Duration of Symptoms vs. Grade of tumour 
Duration Grade 1 Grade 2 Grade 3 Total 
2 months or less 2 (50%) 2 (50%) 0 4 
3-4 months 11 (64.7%) 6 (35.3%) 0 17 
More than 4 months 6 (54.5%) 4 (36.4%) 1 (9.1%) 11 
Total 19 12 1 32 
Chi-square value: 1.666; P= 0.435 
Table 10 Grade of tumour Vs Pathological tumour staging 
Grade of tumour 
Pathological tumour staging 
Total 
T1 T2 T3 
Grade 1 12 (63.2%) 5 (26.3%) 2 (10.5%) 19 
Grade 2 4 (33.3%) 8 (66.7%) 0 12 
Grade 3 1 (100%) 0 0 1 
Total 17 (53.1%) 13 (40.6%) 2 (6.3%) 32 
Chi-square value: 7.356 (P=0.118) 
 Correlation with the smoking with subsite, stage and grade of tumor (table 
11,12,13) has revealed smokers found to have carcinoma tongue twice likely than 
nonsmokers. Floor of mouth and retromolar tumors occurred exclusively in smokers 
and alveolus and hard palate in nonsmokers only. Correlation of smoking with T 
stage and grade was not significant (table 12 and 13) 
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Table 11 Sub-site distribution among smokers & non smokers 
Site Smoker Non- smoker Total 
Alveolus  0 2 (100%) 2 
Buccal mucosa 4 (57.1%) 3 (42.9%) 7 
Floor of mouth 1 (100%) 0 1 
Hard palate 0 2 (100%) 2 
RMT 2 (100%) 0 2 
tongue 12 (66.7%) 6 (33.3%) 18 
Total  19 (59.4%) 13 (40.6%) 32 
Chi-square value: 10.754; P= 0.056 
Table 12 Smoking Vs. tumour staging 
Smoking habit 
Pathological tumour staging 
Total 
T1 T2 T3 
Non smoker 8 (61.5%) 4 (30.8%) 1 (7.7%) 13 
Smoker 9 (47.4%) 9 (47.4%) 1 (5.3%) 19 
Total 17 (53.1%) 13 (40.6%) 2 (6.3%) 32 
Chi-square value: 0.901 (P=0.924)  
Table 13 Grade Vs Smoking 
Smoking 
status 
Grade 1 Grade 2 Grade 3 Total  
Smoker 10 (52.6%) 8 (42.1%) 1 (5.3%) 19 
Non-smoker 9 (69.2%) 4 (30.8%) 0 13 
Total 19 12 1 32 
Chi-square value: 1.666; P= 0.435 
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Alcoholic and tobacco users were analysed for any significant correlation 
between “T” status and grade none were statistically significant (Tables 14, 15). 
Table 14 Alcohol Vs tumour staging 
Alcohol intake 
Pathological tumour staging 
Total 
T1 T2 T3 
Non alcoholic 13 (59.1%) 8 (36.4%) 1 (4.5%) 22 
Alcoholic 4 (40%) 5 (50%) 1 (10%) 10 
Total 17 (53.1%) 13 (40.6%) 2 (6.3%) 32 
Chi-square value: 1.103 (P=0.576)  
Table 15: Smokeless Tobacco usage Vs tumour staging 
Tobacco usage 
Pathological tumour staging 
Total 
T1 T2 T3 
Non tobacco user 10 (43.5%) 11 (47.8%) 2 (8.7%) 23 
Smokeless Tobacco User 7 (77.8%) 2 (22.2%) 0 9 
Total 17 (53.1%) 13 (40.6%) 2 (6.3%) 32 
 Chi-square value: 3.827 (P=0.148)  
 Table 16: Distribution of addictions 
Addictions Frequency Percentage 
No addiction 7 21.9% 
Smoker (or) Alchol (or) smokeless tobacco 11 34.4% 
Any 2 addictions 8 25% 
All  3 addictions 6 18.8% 
Total 32 100% 
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Overview of Sentinel Lymph Node Biopsy 
In 29 SLNB identified neck dissections, 50 sentinel nodes were harvested with 
mean 1.56 nodes.  
Table 17:  Overview of Sentinel Lymph Node Biopsy 
Total No. of patients 32 
No. of patients from whom SLN were harvested 29 
Sentinel lymph node localization rate 90.6% 
No. of patients in whom SLN was positive by Frozen section 5 
No. of false positive by Frozen section 1 
No. of false negative by Frozen section 1 
No.  of patients in whom nodes were positive by enhanced pathological review 1 
No. of patients in whom nodes were positive by Cytokeratin  3 
 
There is considerable variation in the mean number of sentinel node harvest 
with retromolar trigone having the highest yield 2.5 per patient hardpalate has least 
with 1 node per patient. Distribution of total number sentinel lymphnode dissected in 
hard palate, buccal mucosa, tongue, alveolus, floor of mouth and RMT were (2, 9, 28, 
4, 2, 5) and mean is (1, 1.28, 1.56, 2, 2, 2.5) respectively (table 17,18).    
Out of 8 positive nodes, level IB was positive in two patients, IIA positive in 
four patients and Level III was positive in two patients. In the five positive neck 3 
nodes(IB, IIA,III) were harvested in one patient,  two patients with two nodes (IIA,III 
& IB,IIA) and two patients has one node each in IIA level. In these patients except 
two node patients (IIA, III) who had only level III positive, all the other patients had 
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all sentinel nodes were positive. In the positive neck patient out of 9 nodes harvested 
8 were positive for occult metastasis (table 19).  
Table 18:  Distribution of tumour and sentinel nodes 
Site of tumour 
No. of 
patients 
No. of SLN dissected 
Mean no. of nodes per 
patient 
Alveolus 2 4 2 
Buccal mucosa 7 9 1.28 
FOM 1 2 2 
Hardpalate 2 2 1 
RMT 2 5 2.5 
Tongue 18 28 1.56 
Total 32 50 1.56 
Table 19: Analysis of 5 SLNB positive patients 
S NO Level of SLNB No of positivity 
1 IB,IIA,III IB, IIA, III positive 
2 IIA IIA positive 
3 IIA, III III positive 
4 IB,IIA IB,IIA positive 
5 IIA IIA positive 
When analyzing the factors affecting the nodal positivity all the 5 positive 
patients were carcinoma tongue. Patients with T1, T2 were involved in 3 (21.4%), 2 
(15.4%). Well, moderately, poorly differentiated were involved in 3 (17.6%), 1 
(9.1%), 1 (100%) respectively. None of factors were found to have statistically 
significant (table-20). 
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Table 20: Factors affecting sentinel node positivity 
Patient characteristics  Sentinel node frozen section Total significance 
Positive  Negative  
Site of 
tumour 
Non tongue 0 13 (100%) 13 P=0.029 
Tongue 5 (31.2%) 11 (68.8%) 16 
Total 5 (17.2%) 24 (82.8%) 29 
Duration 2 months or 
less 
1 (33.3%) 2 (66.7%) 3 P= 0.678 
 
3-4 months 2 (12.5%)  14 (87.5%) 16 
>4 months 2 (20%) 8 (80%) 10 
Total 5 (17.2%) 24 (82.8%) 29 
“T” status T1 3 (21.4%) 11 (78.6%) 14 P= 0.621 
 T2 2 (15.4%) 11 (84.6%) 13 
T3 0 2 (100%) 2 
Total 5 (17.2%) 24 (82.8%) 29 
Grade Grade 1 3 (17.6%) 14 (82.4%) 17 P= 0.128 
Grade 2 1 (9.1%) 10 (90.9%) 11 
Grade 3 1 (100%) 0 1 
Total 5 (17.2%) 24 (82.8%) 29 
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FACTORS AFFECTING SENTINEL NODE IDENTIFICATION: 
Sentinel lymph node localization rate 90.6% and 3 patients who were not 
identified are >50 years and male. Tongue, T1 tumors and well differentiated tumors 
were the factors for non-identification in two out of three patients (table 21).  
Table 21: Factors Affecting Sentinel Node Identification  
Patient Characteristics Sentinel node status 
Total P Value 
Identified Not identified 
Age 
group 
< 50 years 14 (100%) 0 14 0.114 
≥50 years  15 (83.3%) 3 (16.7%) 18 
Total 29 (90.6%) 3 (9.4%) 32 
Sex Male 21 (87.5%) 3 (12.5%) 24 0.555 
Female 8 (100%) 0 8 
Total 29 (90.6%) 3 (9.4%) 32 
Subsite Alveolus 2 0 2 0.9 
Buccal mucosa 6 (85.7%) 1 (14.3%) 7 
FOM 1 0 1 
Hardpalate 2 0 2 
RMT 2 0 2 
Tongue 16 (88.9%) 2 (11.1%) 18 
Total 29 (90.6%) 3 (9.4%) 32 
Tumour 
Stage 
T1 14 2 16 0.722 
T2 13 1 14 
T3 2 0 2 
Total 29 (90.6%) 3 (9.4%) 32 
Grade of 
tumour 
Grade 1 17 (89.5%) 2 (10.5%) 19 0.886 
Grade 2 11 (91.7%) 1 (8.3%) 2 
Grade 3 1 (100%) 0 1 
Total 29 (90.6%) 3 (9.4%) 32 
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Sentinel lymphnode commonly harvested in level IIA and IB next common 
sites include level III and IA. In level IIB and IV none of the SLNB was identified. In 
32 neck dissections 13 (1.8%) nodes were positive out of 707 (mean 22) nodes 
harvested with maximum yield of nodes in level III and IIA. 
Table 22: Distribution of metastasis in the neck dissection 
Level  
Total no. of LN 
harvested 
Mean no. of LN 
harvested 
LN’s positive on 
HPE 
Distribution of 
Sentinel node  
Ia 89 2.78 (0-6) 0 4 
IB 104 3.25 (1-8) 4 20 
IIa 145 4.53 (2-10) 6 21 
IIB 98 3.06 (1-6) 0 0 
III 149 4.66 (1-12) 3 5 
IV 114 3.56 (0-12) 0 0 
V 22 4.4 (0-6) 0 0 
Total 707 22.09 13 50 
 
When analyzing the factors contributing to nodal positivity it was found all 
were non tobacco users. Non alcoholic and non smokers are at high risk than 
alcoholic and smokers (3 vs 2). Comparing the “T” status T1, T2, and grade 1, 2, 3 
were involved in 12.5%, 21.4%, 10.5%, 16.7%, and 100% respectively. However 
none of the factors turned out to be significant enough to make a difference.    
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FACTORS AFFECTING PATHOLOGICAL NODE POSITIVITY 
Table 23: Factors affecting pathological node positivity 
Patient Characteristics Pathological node status Total P Value 
Positive  Negative  
Tobacco 
usage 
Non tobacco user 5 (21.7%) 18 (78.3%) 23 0.134 
Tobacco user 0 9 (100%) 9 
Total 5 (15.6%) 27 (84.4%) 32 
Smoking Non smoker 3 (23.1%) 10 (76.9%) 13 0.345 
Smoker 2 (10.5%) 17 (89.5%) 19 
Total 5 (15.6%) 27 (84.4%) 32 
Alcohol 
intake 
Non alcoholic 3 (13.6%) 19 (86.4%) 22 0.651 
Alcoholic 2 (20%) 8 (80%) 10 
Total 5 (15.6%) 27 (84.4%) 32 
Tumour 
Stage 
T1 2 (12.5%) 14 (87.5%) 16 0.568 
T2 3 (21.4%) 11 (78.6%) 14 
T3 0 2 (100%) 2 
Total 5 (15.6%) 27 (84.4%) 32 
Grade Grade 1 2 (10.5%) 17 (89.5%) 19 P=0.126 
Grade 2 2 (16.7%) 10 (83.3%) 12 
Grade 3 1 (100%) 0 1 
Total 5 (15.6%) 27 (84.4%) 32 
 
Immunohistochemistry using Pan-Cytokeratin analysis showed 8 out of 29 
were positive (figure-7). This protocol sentinel node assisted neck dissection 
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converted 5 patients to MRND-1 out of 32 patients (figure - 8). Surgical procedures 
performed in this study were enumerated in the diagram (figure - 9). Out 14patients 
who underwent reconstruction are as in (figure- 10). Post treatment adjuvant 
treatments given to these patients were as in (figure - 11). 
Out of 32 patients 8(25%) patients harbor metastasis in the lymphnodes. These 
patients were upstaged, considering the factors affecting stage migration, stage 
subsite were taken into account. Of these factors increasing “T’ status increases 
chance of migration T1 vs T3 ( 25% vs 50%). Tongue is the most common site to be 
upstaged and followed by alveolus and buccal mucosa. Among the grade of lesion 
poorly differentiated tumours were upstaged commonly rather than well differentiated 
tumours (100% vs 31%). (Table 24) 
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Figure -7: Cytokeratin analysis of sentinel nodes: 
 
Figure – 8: Types of neck dissection performed: 
 
Figure -9: Types of procedure performed 
 
Positive: 8 
(28%) 
Negative: 21 
(72%) 
Supra-
omohyoid 
dissection: 27 
(84%) 
Modified 
radical neck 
dissection: 5 
(16%) 
Hemiglossecto
my: 14 (44%) 
Wide local 
excision: 9 
(28%) 
Palatoalveolar 
resection: 4 
(12%) 
Wide local 
excision+ 
Marginal 
mandibulecto
my: 4 (13%) 
Wide local 
excision+ 
Periosteum: 1 
(3%) 
Sentinel Lymph Node Biopsy in Oral Cancers 
 
49 
 
Figure- 10: Reconstruction n= 14 
 
Figure -11: Adjuvant treatment in 32 patients: 
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Table 24: Factors affecting Stage migration 
Patient characteristics N Frozen HPE Cytokeratin 
Clinical 
Stage 
T1 16 3 (18.8%) 2 (12.5%) 4 (25%) 
T2 14 2 (14.3%) 3 (21.4%) 3 (21.4%) 
T3 2 0 0 1 (50%) 
Subsite RMT 2 0 0 0 
FOM 1 0 0 0 
Alveolus 2 0 0 1 (50%) 
Hardpalate 2 0 0 0 
Buccal mucosa 7 0 1 (14.3%) 1 (14.3%) 
Tongue 18 5 (27.8%) 4 (22.2%) 6 (33.3%) 
Grade Grade 1 19 3 (15.8%) 2 (10.5%) 6 (31.3%) 
Grade 2 12 1 (8.3%) 2 (16.7%) 1 (8.3%) 
Grade 3 1 1 (100%) 1 (100%) 1 (100%) 
 
EVALUATION OF FROZEN SECTION OF SLN AS A SCREENING TEST: 
Table 25: Lymph node positivity based on technique 
Nodal identification 
technique 
SLN identified n=29 SLN Non 
identification n=3 Positive Negative 
Frozen section (n=29) 5 24 00 
HPE (n=32) 4 1 negative 
Cytokeratin (n=32) 4 4 negative 
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 Out of 32 patients sentinel lymphnode identified in 29 patients using frozen 
section, which on later date using serial section and study found one false positive and 
false negative which was confirmed by cytokeratin in addition to three patients with 
metastasis. When frozen, HPE and cytokeratin were used as screening test its 
sensitivity, specificity, false negative, false positive, positive predictive value and 
negative predictive value as given in tables  26, 27.28  
Table26: Frozen section positivity Vs Pathological node status 
 Frozen 
section SLN 
pN Status Total 
Efficacy of frozen section 
Positive Negative 
Positive  4 1 5 Sensitivity: 80% PPV: 80% 
Negative 1 23 24 Specificity: 95.8% NPV: 95.8% 
Total 5 24 29 False (+) : 4.2% False (-) : 20% 
Table 27: Frozen section of SLN Vs Cyokeratin positivity 
 
  
Frozen section 
SLN 
Cytokeratin  Total 
Efficacy of Cyokeratin 
Positive Negative 
Positive  4  1  5  Sensitivity: 50% PPV: 80% 
Negative 4  20 24 Specificity: 95.2% NPV: 83.3% 
Total 8  21 29 False (+) : 4.8% False (-) : 50% 
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Table 28: Evaluation of HPE (Pn) against Cytokeratins 
HPE Cytokeratin results 
Total Efficacy of HPE 
Positive Negative 
Positive  4  1 5 Sensitivity: 50% PPV: 80% 
Negative 4 20  24  Specificity: 95.2% NPV: 83.3% 
Total 8 21  29 False (+) : 4.8% False (-) : 50% 
 
Sensitivity of sentinel node biopsy of using frozen section was 80% and 
specificity of 95.8% with negative predictive value of 95.8% when enhanced 
pathological review are considered as standard.  
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  DISCUSSION 
We conducted a pilot study to evaluate the feasibility and efficacy of sentinel 
lymph node assisted neck dissection using methylene blue dye in clinically node 
negative early stage oral cavity cancers at Government Royapettah Hospital. The 
results were as follows 
Patient Demographics: 
Age & sex: In our study, we had 32 patients of whom 24 (75%) were male and 
8(25%) were female. The age distribution is 26-70 (mean 43 years). Stoeckli 
(86)
 et al 
studied 79 patients the mean age was 57 years. The male: female ratio was 53:26. 
Agarwal 
(87)
et al (2011) in their study of 111 patients presenting with oral cavity 
cancer,90 (81%) were male and 21 (19%) were female.  
 Our patients were 10 years younger than what is reported in literature.  
Site & distribution: In the present study, tongue was the most common site involved 
in 18(56.3%), followed by buccal mucosa 7 (21.9%) hard palate, retro-molar trigone, 
RMT and the least common is the floor of mouth.  In a study by Stoeckli 
(86)
 et al oral 
tongue was the most common subsite and buccal mucosa was the least common 
subsite. Shenoi 
(88) 
et al reported in 2012 the buccal mucosa subsite distribution as 
23.73%, mandibular alveolus 45.76%, tongue 18.31%, lips 3.05%, FOM 2.03% and 
palate 1.36%. Agarwal 
(87) 
et al (2011) in their 111 patient’s found to be buccal 
mucosa (41%) to be the commonest. 
In contrast to literature of western world where buccal mucosa is the least 
common which forms the second most common sub site in our population probably 
due to increased use of non-smoke tobacco products. 
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T status & grade: Stoeckli 
(86)
 et al studied 79 patients with early stage T1&T2 oral 
cavity squamous cell cancer without clinical and radiological evidence of cervical 
lymph nodes. One hundred and eleven patients studied by Agarwal 
(87) et
 al 51 each 
(46%) were well differentiated and moderately differentiated, whereas, 9 (8%) were 
poorly differentiated cancers 39%) presented with early stage disease (i.e. stage I and 
II). 
 In our study clinical Tumour status among our patients was T1-16 (50%), T2-
14 (43.7%), and T3-2 (6.3%). Well differentiated, moderately differentiated and 
poorly differentiated occurred in 19(59.3%), 12(37.5%), 1(3.2%) respectively which 
is consistent with the reported literature. Distribution of grade was in par with 
literature however most of our patients presented with advanced stage. In early stage 
T1 and T2 were in equal distribution.  
Patient Presentation:  
Duration & symptoms: Shoenoi 
(88) 
et al 2012 showed 68.14% presented within 6 
months and ulcer with mass is the most common presenting symptom. In another 
study by Agarwal 
(87)  
 et al (2011) the most common presenting symptom was a 
mass/ulcer in the oral cavity, followed by pain, dysphagia and trismus.   
   In this study 17 (53.12%) patients had 3-4 month of symptoms before they 
sought medical attention and 4 (12.5%) presented within two months, however 11 
(34.38%) patients reported after >4 months of symptoms Most of our patients 
presented with ulcer 18 (56.3%), followed by ulcer with pain 12(37.5%). Other 
symptoms like hyper salivation, difficulty in swallowing and referred otalgia were 
less common 
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Morphology: In Agarwal 
(87) 
et al’s 111 patient’s tumour mass was exophytic/ 
proliferative in appearance in 99 patients and ulcerative/infiltrative in the rest.  
In our study Ulcero-proliferative type of growth was the most common 
morphology observed in 16 (50%) patients and the other types  ulcerative, infiltrative 
and verrucous seen in 8 (25%), 6 (18.8%) and 2 (6.3%) respectively. Right and left 
sided lesions were in equal distribution.  
Risk factors: 
 Major risk factor includes tobacco chewing, smoking and alcohol intake alone 
or in combinations and viral infection have been implicated in head and neck 
carcinogenesis. 
Single vs. multiple: Shenoi 
(88) 
et al (2012) reported tobacco chewing alone in 
31.86%, smoking alone in 15.93% and alcohol alone in 5.42%. Tobacco chewing 
with smoking or alcohol occurred in 18.6% and 7.12% respectively, all the three 
occurred in 15.93%. A wide variety of tobacco habits like smoking, chewing, 
snuffing, using burnt tobacco as powder or paste are prevalent in India,  which is 
more so in the rural population than in their urban  counterparts (National Sample 
Survey Organization, 1998). Smoking is most common form of tobacco consumption 
among males and smokeless tobacco among females (National Sample Survey 
Organization, 1998). The same Survey has shown that the tobacco consumption has 
decreased in both urban and rural males and females over the period 1987-94. 
Contrary to the popular belief that the tobacco consumption is increasing, this data 
shows that it has decreased in all sectors. 
In our study 19 patients were smokers, 10 were alcoholic and 9 patients used 
tobacco quid. 21.9% of our patient did not have any addiction. In this study 34.4%, 
Sentinel Lymph Node Biopsy in Oral Cancers 
 
56 
 
25%, 18.8% were addicted to one, two and all the three habits respectively. 
Carcinoma of oral tongue was the most common cancer among the smokers (67% p= 
0.056) in our study. However alcohol, tobacco quid or other addictions did not reach 
significance level as causative agent in our study.  
Non-invasive imaging: 
 Imaging modalities which rely on morphological parameters like Ultrasound 
and CT scan have been used in detecting metastasis with varying results 
(24-27)
.
 
  
Debate persists over relative merits of imaging in evaluation of N0 neck 
(24-27).
  
Studies that correlate radiological and histopathological findings show that early 
microscopic metastasis can be present in lymphnode smaller than 10mm
.
 These nodes 
do not show central necrosis or extracapsular disease. We used ultrasound of the neck 
in all our patients before they were subjected to SLNB. The ultrasound of neck was 
not able to identify any metastatic node in the study patient.
 
 
Sentinel lymphnode biopsy: 
Identification rate, factors affecting them: In a Multi- Institutional Prospective 
Study, Ross 
(89) 
et al reviewed the data from 22 centers and 316 patients with 
clinically N0 neck. The SLNB identification rate was 95% with a overall sensitivity 
of 90%. The sensitivity increased to 94% after exclusion of data from low volume 
centers (<10 patients). Alkureishi 
(90)
 reported an identification rate of (93%, 125/134 
patients), with lower rates for FOM (88% vs. 96%, P = 0.14). Overall detection rates 
for sentinel neck nodes are greater than 95% and there is also a negative predictive 
value of 95% for SLNB
(91,92)
.  
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 In our study, 29 (90.6%) patients sentinel lymphnode were identified and in 
three patients (9.4%) sentinel nodes could not be demonstrated which is low 
compared to reported literature. All the 3 patients were males above 50 years. Two 
out of three where T1, well differentiated and tongue tumor. 
Sentinel node positivity: Out of 32 neck dissection, 50 sentinel nodes was harvested 
with a mean of 1.56 nodes which is less than that reported in literature. In the 50 
harvested nodes 8 (16%) showed metastasis. Out of 29 patients, 5 patients (17.2%) 
were positive for occult metastasis on frozen section. On further histopathological 
evaluation using step sectioning, one was false positive and the other was false 
negative. Three patients (10.3%) found to have micro metastasis using cytokeratin 
after histology reported benign disease. Out of 5 positive samples, level IB showed 
sentinel node in 2 patients, level IIA positive in 4 patients and Level III in two 
patients. Three level of nodes(IB, IIA,III) were harvested in one patient,  two level of 
nodes in two patients (IIA,III & IB,IIA) and the next two patients had one node each 
in IIA level. When tumor stage and grade were compared no significant correlation 
could be seen (table-20). 
Stage migration: In study by Alkureishi 
(90) 
et al 42 patients were upstaged by SNB 
(34%), with 10 patients having micro metastatic disease detectable only by SSS (n = 
2) or IHC (n = 8).  
 In our study 8 out 32 patients (25 %) where upstaged using enhanced 
pathological review and IHC. T1 tumors (25%) and T3 tumors (50%) likely to 
undergo stage migration. Carcinoma tongue is the most common site to be upstaged; 
others include alveolus and buccal mucosa. Poorly differentiated tumors as compared 
to well differentiated tumors are more likely to undergo stage migration.  
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Intra-operative Frozen section Vs. Enhanced Pathological review Vs. IHC:  
Serial sectioning, immunohistochemistry (IHC), and reverse transcriptase 
polymerase chain reaction (RT-PCR) may identify metastases missed by standard 
processing 
(73-80)
. Although intraoperative frozen section has been evaluated for SNB, 
its sensitivity is not very high (60%), and an inherent problem with intraoperative 
frozen section is sampling error, because even one or two 5-mm frozen sections of a 
1-cm LN only corresponds to 0.1%, which is visually analyzed and therefore may 
miss metastasis
(73-80)
. This is particularly true if the metastatic deposit is located near 
the capsule, as opposed to the mid-portion when the node is bivalved into two 
sections. Frozen-section histology is also subject to technical difficulties in sample 
and section preparation, including interpretive challenges, all of which are heavily 
dependent on the skill and experience of the pathologist and support staff. Even 
though final assessment of step-sectioned formalin-fixed, paraffin embedded sections 
is the gold standard and samples a larger percentage of the node. It can underestimate 
the tumor burden because it may not find micro metastatic deposits (<2 mm and >0.2 
mm), and ITCs (tumor clusters <0.2 mm). This fact is indirectly suggested by “7% to 
10% of pN0 patients after END experience recurrent disease in the neck”. Hence, a 
method of evaluating a large portion of SLN for metastasis that is both rapid and 
accurate would be of great benefit.   
Sensitivity of sentinel node biopsy of using frozen section was 80% and 
specificity of 95.8% with negative predictive value of 95.8% when enhanced 
pathological review is considered as standard. However if micro-metastasis are 
identified using IHC was considered as standard  Frozen section sensitivity drops to 
50% but has specificity 95.2 % and negative predictive value was 83.3%. In the 3 
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patients whom SLN were not identifiable, routine histopathological examination of 
the extended supra-omohyoid specimen were negative as well. In our study we had 
one false positive (Frozen positive HPE Negative) and one false Negative patient 
(Frozen negative, HPE Negative). Cytokeratin analysis revealed additional 3 patients 
harboring micro metastases in the sentinel node which was not detected by frozen 
section and enhanced pathological review. 
Differential spread of tumors: 
  Several forms of differential tumor spread to lymphatics have been 
documented. In overflow phenomenon, advanced metastatic burden in first echelon 
nodes, resulting in embolic spread to lower anatomical levels to create inverted cone 
effect. . Fast tract nodes are those in which have primary drainage to level III and IV 
rather than upper levels. Peppering is isolated tumour cell(s)/ micro metastasis in 
nodes at multiple levels in the absence of macro metastasis. Soft tissue deposit is 
defined as metastasis with in area of lymphatic drainage but without any obvious 
nodal structure. Extracapsular disease occurring in the lymphnode can be 
macroscopic, microscopic and early microscopic. 
In the study by Byers et al 
(93) 
15.8% had either level IV metastasis as the only 
manifestation of disease in the neck or the level III node was the only node present 
without disease in level I-II. Skip metastases occur in carcinoma tongue and FOM 
which has been supported by anatomical studies 
(94)
. Based on this extended 
supraomohyoid dissection became treatment of choice
 (93,94).
 
In our study we did not have any skip metastasis, extracapsular disease and 
soft tissue deposit or overflow phenomenon. Peppering of nodes occurred in 2/5 
(40%) patients. Fast tract node occurred in one patient. Three patients (60%) had only 
Sentinel Lymph Node Biopsy in Oral Cancers 
 
60 
 
one sentinel node as metastatic disease in the neck. If more than one sentinel lymph 
node positive, it is likely that other lymph node(s) are involved. 
Occult metastasis:   
Occult metastases are those that are identified by enhanced techniques after 
being missed on a standard evaluation. They may be micrometastases that are 
identified only by serial sectioning, immunostaining, or RT-PCR. The table 28 shows 
the evidence from the available literature on occult metastasis. 
Table 28: Occult Metastases 
Study No. of Patients Occult Metastases  
Beyers et al (1999)
(93)
 227 SOHND 42% 
Mira et al (2002) 
(95)
 126 SOHND 11% 
De zinis et al (2006) 
(96)
 89 (SOHND+RND) 52% 
Iype et al(2008) 
(97)
 184    SOHND 24.3 % 
Legoux et al 
(98)
 77 ( 62 SOHND+ 15 RND) 32.5% 
   
 Our data has shown 4/32 (12.5%) patients had occult disease which is in par 
with the recent literature. However none of  our patients had extra capsular disease.  
Neck dissection:  
 Pitman KT et al 
(99) 
comparing the modified radical neck and selective neck 
dissection for clinically N0 neck in 436 patients, showed regional recurrence rate of 
5.8% for MRND and 3.5 % for selective neck dissection. The Brazilian Head and 
Neck Cancer Study Group 
(100) 
compared neck recurrence and survival for selective 
and modified radical neck dissection. In that study the regional control and overall 5-
year survival rates were 87.5% and 67% in the selective neck dissection group and 
89.3 % and 63% for MRND group respectively. This data suggest that the selective 
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neck dissection is oncologically comparable to conventional MRND for management 
of N0 neck 
 In our study sentinel node assisted neck dissection study out of the 32 
patients 5 patients underwent MRND-1 and 27 patients had extended Supra Omo-
Hyoid (SOHD) neck dissection.  
Necessity of Level IIB, IV and V clearance:  
 The necessity of Level IIB clearance in oral cavity cancers with N0 disease is 
still debated due to the associated increased chance of injury to spinal accessory nerve 
and subsequent shoulder syndrome, since the risk of level IIB involvement is 2-6% 
(102-105)
. In our study, none of sentinel nodes were identified in the level IIB. Moreover 
out of 98 nodes dissected in the level IIB in 32 patients with a mean of 3 nodes per 
neck dissection none revealed metastasis. Hence level IIB sparing neck dissection is 
sufficient if SLNB is negative. 
 Similarly, in clinically N0 neck involvement of level IV and V are rare 
(107,108)
. 
In our study we have dissected 114 nodes with a mean of 3 nodes per patient in level 
IV. In level V a total of 22 nodes were harvested but all were histologically benign. 
 Recurrence: 
A study by  Carvalho AL
(101)
 et al found that elective neck dissection is often 
used as a staging procedure, but recurrence has been found in 4.5% of the cases and 
this occurred either in the area of neck dissection (57.1%) or beyond (42.9%). 
Considering the six hypothetic scenarios: "only SLN removal", "SLN level 
dissection", "neck dissection from the tumour site to SN level", "selective neck 
dissection of three levels (SOHND)", "dissection from level I to IV"(extended 
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SOHND) and "comprehensive I-V dissection"(MRND), neck recurrences could be 
expected in 6.5%, 3.8%, 2.18%, 2.73%, 1.09% and 1.09% of cases, respectively 
  In our study 2 patient developed recurrences, both occurred in the 
contralateral neck. The first patient developed recurrence after 2 months and second 
patient after 4 months. One had T3 disease and the other had a 3.5 cm tumour. Both 
presented after 8 months of symptom and had carcinoma tongue. They had sentinel 
nodes in ipsilateral IB, IIA which was negative on frozen section and histo-
pathological examination. Adequate nodes were sampled (16 & 31) in the two 
patients and all were negative. But on cytokeratin IHC one patient (T3) was positive 
for micro metastases. This is due to not sampling the contralateral side because of 
non-utilisation of radio colloid technique.  
Disadvantages of our study: 
1. Need to raise subplatysmal flap to identify sentinel lymph node. 
2. Contralateral drainage cannot be identified. 
3. Blue dye stains peritumoral areas making resection margin determination 
difficult 
4. Difficulty in injecting 2 ml in case of hard palate and alveolar subsites(bony). 
5. Blue dye tracking from the peritumoral areas to neck level from FOM lesion 
makes identification of SLN difficult. 
6. Small sample size. 
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SUMMARY OF RESULTS: 
In our study of 32 patients we had male: female 75%:25% ratio with mean 
age of 43.15 yrs (range: 26-70). Tongue (56.3%), buccal mucosa are the two 
common sub-sites, FOM is the least common. In western literature, buccal mucosa 
is the least common subsite as opposed to Indian population. This disparity is due 
to peculiar habit of using smokeless tobacco among our people. Our study included 
19 smokers, 9 using tobacco quid and 10 were alcoholics. Carcinoma of oral 
tongue was the most common cancer among the smokers (p= 0.056). Our patients 
presented with ulcer (56.3%), or ulcer with pain (37.5%) and most have ulcero-
proliferative (50%) type of tumor morphology. Right and left sided lesions are in 
equal distribution. 53.12% of patients reported for treatment after 3-4 month of 
symptoms and < 12.5% of patients presented within two months. 
In this SLNB study, 50%, 43.7%, 6.3% are T1, T2, T3 tumors, 59.3%, 
37.5% and 3.2% tumors were grade 1, 2 and 3 respectively and USG neck was not 
helpful in detecting occult metastatic nodes.  
 In this pilot study methylene blue dye based SLNB was done (not 
standard practice in head and neck cancer) and all patients electively followed with 
neck dissection.  Sentinel lymphnode identification rate was 90.7% and 50 (mean 
1.56) sentinel nodes were identified. Retro-molar trigone had the highest yield of 
SLN (mean 2.5) per patient; hard palate had least with (mean 1) node per patient. 
Level IIA was the most common level for SLN (17.2%) positivity for occult 
metastasis on frozen section. Out of the five patients all were carcinoma tongue 
and 60% of them were T1, grade -1 tumor and 40% were T2 tumor and 20% were 
grade 2, 3 tumor. In these patients 88% of SLN were positive for occult metastasis. 
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Enhanced pathological review facilitated to identify false positive and false 
negative on HPE, 3 patients were upstaged by IHC. Sensitivity, specificity and 
negative predictive value of sentinel node biopsy for using frozen section was 
50%,95.2 %,83.3%  and 80%, 95.8%, 95.8%  when enhanced pathological review 
or IHC was used. In all patients on whom SLNB was non identifiable, 
histopathological examination of neck dissection specimen were also negative.  
 Non-smokers (15.6%) and non-alcoholic (9.3%) are at more risk for 
nodal metastasis than smokers & alcoholic (6.2%). T1 and T2 tumors have 12.5% 
and 21.4% pathological node positivity rates. Increasing grade conferred increased 
risk of nodal metastasis. In our study of sentinel node assisted neck dissection, 
15.6% underwent MRND-1 and 84.4% SOHD.  
In this study no sentinel nodes were identified in the level IIB, nor did any 
nodes positive in this level on neck dissection. Hence Level IIB sparing neck 
dissection may be recommended if SLNB is negative. In this pilot trial we did not 
encounter any skip metastasis, extracapsular disease, soft tissue deposit or 
overflow phenomenon. Peppering of nodes occurred in 40% patients and fast tract 
node occurred in 3.12%. Sentinel node as the only site of metastatic disease 
occurred in 60% and if more than one sentinel lymph node was involved other 
node(s) in the same or other level is likely to be involved as well.  
Our data had shown occult disease in 12.5% of clinically N0 patients. 
However none our patients had extra capsular disease. 6.25% patient developed 
recurrences in the contralateral neck. This reveals the disadvantage of not sampling 
the contralateral side for these patients since only methylene blue dye was used.  
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CONCLUSION 
Sentinel Lymphnode Biopsy (SLNB) addresses some of the complex issues of 
the management of clinically neck node negative oral cavity cancers. SLNB is still in 
early stages of development for head and neck cancers. This pilot study has shown 
that using blue dye alone to identify SLNB, does not meet recommended standard due 
to the lower sentinel lymphnode identification rate and mean node harvest.  
This study has also shown other important results: 
1. The sensitivity, specificity and negative predictive value of sentinel node 
biopsy improved when enhanced pathological review or IHC 
incorporated in the protocol. Hence two staged sentinel procedure 
including both may be considered for further studies. 
2. Level IIA, IB is the most common site of sentinel nodes from oral cancers. 
3. USG imaging is not useful in assessment of occult neck metastases as it is 
observer dependent.  
4. SLNB using methylene blue alone has high Negative Predictive Value.  
5. Absence of sentinel node metastasis has good correlation with negative non-
sentinel nodes.   
6. No incidence of nodal metastases in Level IIB, IV and V in clinically N0 
oral cancers. Routine dissections of these levels may be reconsidered 
among N0 patients to reduce morbidity. 
We anticipate a broader role for SLNB in future for staging and management 
of clinically node negative head and neck cancers. Radiocolloid localisation, IHC, 
Intraoperative RT-PCR and other molecular techniques may improve accurate 
identification of SLNB and detection of micro metastases. 
i 
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ABBREVIATIONS 
 
DFS Disease free Survival 
FOM Floor of Mouth 
HPE Histopathological Examination 
ITC Isolated Tumour Cells 
LN Lymph Node 
LS Lymphoscintography 
Mi Micrometastases 
MRND Modified Radical Neck Dissection 
N+ Clinically Node Positive 
N0 Clinically Node Negative 
RLND Regional Lymph Node Dissection 
RMT Retromolar Trigone 
RND Radical Neck Dissection 
RT-PCR Reverse Transcriptase – Polymerase chain Reactions 
SAN Spinal Accessary Nerve 
SCC Squamous Cell Carcinoma 
SLN Sentinel Lymph Node 
SLNB Sentinel Lymph Node Biopsy 
SND Selective Neck Dissection 
SOHND Supra omohyoid Neck Dissection 
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PROFOMA 
 
Sr.No…………      IP.NO……….. 
Name…………………….   Age……. Sex  a) Male   b) Female 
Date of admission:  Date of surgery:  Date of discharge: 
Address……………………………………………………………. Occupation…………. 
Patient History: 
Religion:  a) Hindu b) Christian c) Muslim d) others 
Marital status:   a) Married b) Unmarried  c) Widow 
Family H/o Cancer:    a) Yes  b) No  c) Don’t know 
Family h/o Head and neck cancer: a) Yes  b) No         If YES: details: 
Any pre- cancerous lesion or condition: …………………….. 
Habits: a) Yes       b) No     If yes: a) tobacco chewing   b)  pan    c) smoking   d) alcohol 
Duration: a) <1 yr   b) 1-5 yr   3) > 5 yr. 
Co-morbid factors            a.DM  b.HT  c. IHD  d. COPD e. Others: specify……… 
Previous Neck surgery:  a)Yes   b)No   If Yes – Excluded    Previous treatment 
of primary  ………………………………… 
Symptoms : Duration of symptoms in months             a) 1  b) 2-3  c) 4-6   d) >6   
local pain  ulcer  Bleeding   Aspiration  
Trismus  Dysphagia  Referred otalgia  Hypersalivation  
Voice Change  Neck swelling   Others    
Examination: 
Number of lesions    a) single b) Multiple.  
Side        a) Right   b) Left    c) Midline d) Bilateral  e) Crossing  midline 
Type of growth         a)Ulcero-proliferative  b)verrucous  c)infiltrative  
Size of lesion   a) Length ……cms  b)Breadth……….cms 
Extension to adjacent sites            a)yes  b)no If yes specify………………………. 
Clinical Neck Nodes                a)Yes   b)No   If Yes – Excluded 
USG Neck …………………………………………… 
Diagnosis: Clinical T  N0 M0           a)Stage-1 b)Stage-2 c)Stage-3 d)Stage-4               
         Pre op HPE………………………………… Grade        ….....................   
  
x 
 
Management:   
Surgical treatment of neck:        a) SOHND  b) MRND  c) RND 
Surgical reconstruction:      a) Nil  b)PMMC c) DP  d) Forehead e) others 
Sentinel Node Biopsy details 
Level No. of Nodes Frozen Section 
Positive/Negative 
Final HPE Positive/Negative/ Micro 
metastases/ ITCs 
Cytokeratin 
Positive/Negative 
IA     
IB     
IIA     
IIB     
III     
IV     
V     
 
Elective Neck Dissection details 
Level No. of Nodes Final HPE:Positive/Negative/ Micro metastases/ ITCs 
IA   
IB   
IIA   
IIB   
III   
IV   
V   
Adjuvant Details:  A) Chemotherapy B) Radiotherapy  C) Others 
Details of Chemo/RT………………………………………………………… 
Recurrence in primary    
Nodal recurrence    
Metastasis    
Others    
Details of Treatment of recurrence ……………………………………….  
  
xi 
 
INFORMED CONSENT  
 
SL NO ……..                                IP NO…………. 
Name…………………………..        Age ……….         Sex……………. 
 Date of Admission ………………             Date of surgery…………….. 
Address…………………………………………………………………….. 
 
I’m suffering from oral cavity cancer. This cancer frequently affects lymphnodes and later it 
spreads to distant sites. Multimodality approach like Surgery, Radiotherapy and Chemotherapy are 
used to treat such cancer. Neck dissection surgery is treatment for cancer involvement of neck 
nodes in which lymphatic tissues are removed as a part of treatment. Neck dissection may lead to 
minor complication like seroma formation or at times major complications like bleeding and it can 
be acute , sub-acute or chronic. Few of which are bleeding at the time of surgery or delayed, air-
way obstruction, nerve damage, chylous fistulae, infection, flap necrosis etc… 
 Alternative treatment includes Radiotherapy to neck and you have 100% right to refuse to 
participate in this project. Department of surgical oncology, GRH, Chennai-14 has started a project 
with the aim to diagnose involvement of neck nodes before they become palpable and will facilitate 
to identify early spread of cancer to neck and plan accurate treatment. We will first use the blue dye 
to identify sentinel node and then proceed to Selective Neck Dissection (SND) /Modified Radical 
Neck Dissection (MRND)/. Our research group will be very thankful for your support & co-
operation. 
 I have studied and under-stood well all the points and I give free consent for my enrolment 
in above study whole heartedly. 
 
 
 
Date:  
Place:                                                                                                    Signature                                                                                       
 
 
Signature of witness 
Name & Contact no 
Name ag
e
 
se
x
IP
 n
o
R
e
li
gi
o
n
Occupation
Fa
m
il
y 
H
is
to
ry
C
o
m
o
rb
id
it
ie
s
Premalignant 
conditions
sm
o
ki
n
g
A
lc
o
h
o
l
To
b
ac
co
 c
h
e
w
in
g
O
th
e
r 
A
d
d
ic
ti
o
n
s
Symptoms
Sy
m
p
to
m
 D
u
ra
ti
o
n
Site
mani 48 M 960025 hindu watchman normal no no 35 yrs no yes hans ulcer 24 buccal mucosa
thiruvenkadam 55 M 963039 hindu flower vendor normal no no no yes 30 yrs no ulcer 3 hardpalate
prema 40 F 962282 hindu cooly normal no no no no no no ulcer, pain 2 tongue
viswanathan 55 M 963837 hindu cooly normal ht no 15 yrs 15 yrs no no ulcer 8 tongue
baskar 43 M 964364 hindu cooly grand mother ht  leucoplakia no no 20 yr no pain, ulcer 3 tongue
rathiannamal 58 F 964465 christian home maker normal no no no no no no ulcer , otologia, hypersalivation 5 tongue
eallamal 70 F 964803 hindu cooly normal no no no no 40 yrs no ulcer 4 buccal mucosa
vijayakumar 32 M 964626 hindu mechanic normal copd no 7 yrs no 5 yrs pan ulcer, pain 5 tongue
loganathan 56 M 967687 hindu carpenter normal no no 30 yrs 30 yrs no no ulcer 6 tongue
varadarajan 60 M 966124 hindu agriculturist normal dm no 35 yrs no no no ulcer, pain 3 tongue
thangarasu 40 M 967446 hindu electrician normal no no 20 yrs 15 yrs no no ulcer, pain 3 tongue
jeyaraj 54 M 968502 christian agriculturist normal no leukoplakia 30 yrs no no no ulcer 3 tongue
ramakrishnan 49 M 969310 hindu cooly normal no no 25 yrs no no no ulcer 3 buccal mucosa
lawrence 46 M 972058 christian salesman normal no no no no no no ulcer 2 tongue
baradhan 70 M 972950 hindu cooly normal no no 40 yrs 35 yrs no no ulcer 5 tongue
vasantha 55 M 975161 hindu home maker normal no no no no no no ulcer 1 buccal mucosa
jeyaraman 62 M 976100 hindu gardner normal no no 30 yrs no 10 yrs pan ulcer, pain dysphagia 6 tongue
kannumayil 62 F 976016 hindu cooly normal no no no no no no ulcer, pain 8 tongue
marimuthu 51 M 982487 hindu agriculturist normal no no 25 yrs no no no ulcer 4 buccal mucosa
nagaraj 31 M 982423 hindu cooly normal no no 15 yrs 10 yrs no no ulcer, pain 4 tongue
rebel 58 M 985045 christian cooly normal no no 25 yrs no no no ulcer, pain 3 tongue
sekar 55 M 983674 hindu cooly normal no no 23 yrs 20 yrs no no ulcer 1 fom
velayutham 42 M 988608 hindu cooly normal no no 20 yrs no no no ulcer. Pain 3 rmt
varalakshmi 43 F 991452 hindu home maker normal no no no no no no ulcer 3 tongue
veerasamy 65 M 991956 hindu agriculturist normal no no 36 yrs no no no ulcer 4 buccal mucosa
illamalli 55 F 993341 hindu cooly normal no no no no 35 yrs no ulcer 6 alveolus
janakiraman 26 M 999676 hindu mechanic normal no no 12 yrs 10 yrs no pan 10 yrs ulcer pain 4 tongue
kaliyaperumal 65 M 998266 hindu agriculturist normal no no 30 yrs 25 yrs no  no ulcer pain 5 rmt
parthiban 45 M 100674 hindu salesman normal no no 20 yrs 20 yrs no pan 15 yrs ulcer 3 tongue
rama 47 F 102479 hindu cooly normal no post cricoid web no no 20 yrs no ulcer 3 alveolus
neela 45 F 111091 hindu home maker normal no no no no no no ulcer, pain 6 buccal mucosa
krishna moorthy 57 M 111543 hindu agriculturist normal no no no no 30 yrs pan 20 yrs ulcer 3 hardpalate
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4x3 ulceroproliferative one right 2 scc 1 Wide Local Excision nasolabial sohd Ib, II 2 negative 2 0 1 0 6 0 5 0 1 0
ulcer one left 2 scc 1 palatoalveolar resection obturator sohd Ib 1 negative 3 0 3 0 10 0 2 0 3 0
3x2 ulceroproliferative one right 2 scc 2 hemiglossectomy nil mrnd-1 Ib, Iia, III 3 positive 3 0 3 2 3 2 2 0 4 2
1.5 x 1 infiltrative one left 1 scc 3 hemiglossectomy nil mrnd-1 Iia 1 positive 2 0 5 0 2 0 5 0 8 0
3.5x 2 ulceroproliferative one left 2 scc 1 hemiglossectomy nil sohd III 1 negative 3 0 3 0 10 0 2 0 10 0
3.5x 2.5 ulceroproliferative one left 2 scc 2 hemiglossectomy nil sohd Ib 1 negative 4 0 3 0 7 0 2 0 9 0
1.5x1 verrucous one left 1 scc 1 Wide Local Excision ssg sohd IB 1 negative 2 0 1 0 3 0 4 0 8 0
1.5x 1 ulcer one left 1 scc 1 Wide Local Excision nil mrnd-1 Iia III 2 III positive 3 0 4 0 7 0 2 0 10 0
2x 3 ulceroproliferative one right 2 scc 1 hemiglossectomy nil sohd Ib, Iia 2 negative 4 0 8 0 3 0 2 0 5 0
2x 1.5 ulcer one right 1 scc 2 hemiglossectomy nil sohd no no no 2 0 6 0 7 0 3 0 5 0
5x4 infiltrative one right 2 scc 1 hemiglossectomy nil mrnd-1 Ib, II 2 positive 1 0 3 2 5 1 6 0 5 0
3.2x 1.5 infiltrative one right 2 scc 1 hemiglossectomy nil sohd IIa,III 2 negative 2 0 4 0 2 0 1 0 2 0
3x2 ulceroproliferative one left 2 scc 2 Wide Local Excision ssg sohd Ia, Ib 2+1 negative 3 0 2 0 4 0 6 0 3 0
1X1.5 verrucous one right 1 scc 1 Wide Local Excision nil sohd Ib 2 negative 3 0 3 0 4 0 3 0 2 0
3x 2 ulcer one left 2 scc 1 hemiglossectomy nil sohd no no no 3 0 2 0 4 0 2 0 3 0
2x2 ulceroproliferative one right 1 scc 1 Wide Local Excision ssg sohd no no no 0 0 2 0 5 0 2 0 4 0
5x2 infiltrative one left 2 scc 2 hemiglossectomy nil sohd Ib 2 negative 1 0 2 0 2 0 6 0 1 0
5x 2.5 ulceroproliferative one right 3 scc 1 hemiglossectomy nil sohd Ib, II 2 negative 6 0 4 0 5 0 4 0 4 0
2x1 ulceroproliferative one left 1 scc 2 Wide Local Excision ssg sohd Iia 1 negative 4 0 3 0 3 0 2 0 3 0
2x1.5 infiltrative one left 1 scc 1 hemiglossectomy nil sohd Iia 1 negative 4 0 5 0 7 0 5 0 3 0
2x2 ulcer one left 2 scc 2 Wide Local Excision nil sohd Ib 2 negative 3 0 4 0 3 0 4 0 12 0
2.5 x 1.5 ulceroproliferative one right 2 scc 2 Wide Local Excision + MM local sohd ib 2 negative 3 0 6 0 6 1 2 0 1 0
2x1.5 ulcer one right 1 scc 2 Wide Local Excision + MM local sohd Iia 2 negative 6 0 1 0 4 0 1 0 7 0
2x3 ulceroproliferative one right 1 scc 1 Wide Local Excision nil mrnd-1 Iia 1 positive 3 0 4 0 3 1 3 0 1 0
3.5x2 ulceroproliferative one left 1 scc 1 Wide Local Excision+ periosteum local sohd Ia 1 negative 0 0 4 0 5 0 2 0 6 0
2x2 ulceroproliferative one left 1 scc 1 palatoalveolar resection obturator sohd Ib, Iia 2 negative 5 0 2 0 3 0 2 0 7 0
5x4 infiltrative one right 3 scc 1 hemiglossectomy nil sohd Ia, Iia, III 3 negative 4 0 1 0 3 0 3 0 2 0
2x1 ulceroproliferative one left 1 scc 2 Wide Local Excision+ MM local sohd Ia, Iia 2+1 negative 0 0 2 0 2 0 2 0 1 0
3.5x3 ulceroproliferative one right 1 scc 1 hemiglossectomy nil sohd Iia 1 negative 3 0 2 0 4 0 2 0 10 0
3x3 ulcer one right 1 scc 1 palatoalveolar resection obturator sohd Iia 2 negative 0 0 3 0 6 0 5 0 6 0
3x2 ulceroproliferative one left 2 scc 2 Wide Local Excision + MM local sohd Ib 1 negative 3 0 7 2 2 0 4 0 1 0
2x1.5 ulcer one right 1 scc 2 palatoalveolar resection obturator sohd Iia 1 negative 4 0 1 0 5 0 2 0 2 0
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5 0 0 0 20 0 1 0 nil no nil no 26 Negative
4 0 0 0 18 0 1 0 nil no nil no 26 Negative
3 0 3 0 21 4 2 2b nil RT nil no 25 Positive
3 0 4 0 29 1 1 1 nil no nil no 24 Positive
2 0 0 0 28 0 2 0 nil no nil no 24 Negative
2 0 0 0 27 0 2 0 nil no nil no 25 Negative
10 0 0 0 28 0 1 0 nil no nil no 24 Negative
7 0 5 0 38 0 1 0 nil no nil no 23 false positive slnb Negative
3 0 0 0 25 0 2 0 nil no nil no 23 Negative
0 0 0 0 23 0 2 0 nil no nil no 23 no
7 0 6 0 33 1 2 1 nil yes nil no 22 Positive
1 0 0 0 12 0 2 0 nil no nil no 22 Positive ITC
2 0 0 0 20 0 2 0 nil no nil no 21 Negative
3 0 0 0 18 0 1 0 nil no nil no 21 Negative
2 0 0 0 16 0 2 0 nil no nil no 20 no
2 0 0 0 13 0 1 0 nil no nil no 19 no
4 0 0 0 16 0 2 0 nil yes yes 4 19 dead Negative
8 0 0 0 31 0 3 0 nil yes yes 2 15 dead Positive ITC
5 0 0 0 22 0 1 0 nil no nil no 15 Negative
6 0 0 0 27 0 1 0 nil no nil no 15 Negative
1 0 0 0 27 0 1 0 nil no nil no 14 Negative
12 0 0 0 31 0 2 0 nil no nil no 14 false negative Negative
1 0 0 0 20 0 1 0 nil no nil no 11 Negative
6 0 4 0 21 0 1 1 nil no nil no 10 Positive
5 0 0 0 22 0 1 0 nil no nil no 9 Positive ITC
5 0 0 0 24 0 1 0 nil no nil no 8 Positive ITC
3 0 0 0 16 0 3 0 nil yes nil no 7 Negative
0 0 0 0 7 0 2 0 nil no nil no 7 Negative
2 0 0 0 23 0 1 0 nil no nil no 6 Negative
0 0 0 0 20 0 1 0 nil no nil no 5 Negative
0 0 0 0 17 2 2 2a nil no nil no 3 Negative
0 0 0 0 14 0 1 0 nil no nil no 3 Negative
